Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per share from the same period last year.